Facebook
X
LinkedIn
Forward| Title | Credit | Series date | Member price |
Non-member price |
|---|---|---|---|---|
|
Emerging Health Threats in Infants: Congenital Syphilis 0.75 NAPNAP Contact Hour. This continuing education activity is offered free to NAPNAP Members and non-members. Emerging Health Threats in Infants: Congenital Syphilis |
|
04/08/2025 to 04/30/2027 | $0.00 | $0.00 |
|
Clinical Updates in Pediatric Food Allergy Management Pediatric nurse practitioners and others who care for children with FA will benefit from a review of the immunopathophysiology and diagnosis of immunoglobulin E (IgE)-mediated FA and available therapies and data related to the use of biologic therapy in this disease. Experts will discuss the key aspects of FA management and contextualize the information in nurse practitioners’ role in important patient and caregiver conversations and care. |
|
05/15/2025 to 05/15/2026 | $0.00 | $0.00 |
|
Childhood Obesity SIG Course Bundle In this course bundle, three courses have been selected by the Childhood Obesity Prevention Special Interest Group (CO SIG) to increase knowledge related to AAP's 2023 Clinical Practice Guideline for the Evaluation and Treatment of Pediatric Obesity in Primary Care. |
05/16/2025 to 05/31/2026 | $0.00 | $0.00 | |
|
Guidance for Primary Care PNPs During and After Medical/Surgical Treatment of Obesity in Adolescents 1.0 NAPNAP contact hour. This continuing education activity is offered FREE to Members and Nonmembers. The American Academy of Pediatrics (AAP) recently released the ‘Clinical Practice Guideline (CPG) for the Evaluation and Treatment of Children and Adolescents with Obesity’ in early 2023. Updated from the AAP’s 2008 recommendations for prevention, assessment, and treatment of children and adolescents with overweight and obesity, the 2023 CPG offers expanded treatment recommendations which includes medication and surgical management. Pediatric Nurse Practitioners (PNP) may not understand the long-term management and support needs in primary care needed for this population. Discussion of management considerations for the primary care provider include: preventative care and screenings, health promotion, nutrition, body image, physical activity and psychological support. Additionally, recommendations for family and community involvement to support improved long-term care outcomes will be discussed. |
|
05/17/2024 to 05/31/2026 | $0.00 | $0.00 |
|
Mandated Reporting 1.0 NAPNAP contact hour. This continuing education activity is offered FREE to Members and Nonmembers. Should I report my concerns for suspected child maltreatment and neglect? If I do report, how do I know how and what to report? The NAPNAP Child Maltreatment and Neglect SIG discusses key factors in the various typologies of abuse for pediatric-focused advanced practice nurses in determining the need and steps to report child maltreatment and neglect. |
|
06/01/2025 to 06/01/2026 | $0.00 | $0.00 |
|
Tick Talk: Digging Deeper into Lyme Disease 2024 1.0 NAPNAP Contact Hour. This continuing education activity is free to National Association of Pediatric Nurse Practitioners (NAPNAP) members and non-members. This course is a recorded presentation for NAPNAP's 2024 National Conference. Lyme disease is the most common vector-borne disease in the U.S., with a childhood peak at five to nine years of age. Pediatric-focused APRNs in both high and low incidence areas may encounter patients in whom Lyme disease is a concern. This presentation will provide an in-depth review of Lyme disease testing and interpretation, discuss when (and when not) to treat and examine the current knowledge regarding prolonged symptoms. |
|
06/27/2024 to 06/30/2026 | $0.00 | $0.00 |
|
2025 Pediatric Pharmacology Update 1.00 NAPNAP Contact Hour of which 1.00 pharmacology content. This continuing education activity is offered as part of the 2025 Pediatric Pharmacology Bundle. This course is a recorded presentation for NAPNAP's 20255 National Conference. A fast-paced update on pediatric prescribing including newly approved or relabeled pediatric medications, and pediatric pharmacology studies in process. Issues that affect pediatric practice including drug shortages, emerging poisoning hazards, and new guidelines will be discussed. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
Pharmacologic Management of Cardiac Dysrhythmias 1.25 NAPNAP Contact Hour of which 1.25 pharmacology content. This continuing education activity is offered as part of the 2025 Pediatric Pharmacology Bundle. This course is a recorded presentation for NAPNAP's 20255 National Conference. This presentation will focus on the treatment of common dysrhythmias seen in children, specifically pharmacologic options. We will review both inpatient and outpatient management of various dysrhythmias. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
2025 Psychopharmacology Update 2.75 NAPNAP Contact Hour of which 2.75 pharmacology content, 2.75 are Psychopharmacology content and 0.25 are Controlled Substance content. This archived presentation from our 2025 national conference is available only as part of a bundle of pharmacology courses recorded during our 2025 conference in Chicago. Purchase the 2025 Pediatric Pharmacology Bundle and gain access to all five courses. Children and adolescents with behavioral health conditions are commonly seen in all pediatric environments. We will focus on the emerging use of long-acting formulations for management of chronic psychiatric conditions and other new pharmacologic approaches to behavioral health management. This presentation is solely focused on pharmacology and aims to help demystify these medications for the pediatric provider. NAPNAP’s Developmental Behavioral and Mental Health SIG is pleased to support this session. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
New Pediatric Antibiotic Prescribing Guidelines 1.00 NAPNAP Contact Hour of which 1.00 pharmacology content. This archived presentation from our 2025 national conference is available only as part of a bundle of pharmacology courses recorded during our 2025 conference in Chicago. Purchase the 2025 Pediatric Pharmacology Bundle and gain access to all five courses. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
Keeping Current in Atopic Diseases 1.25 NAPNAP Contact Hour of which 1.25 pharmacology content. This continuing education activity is offered as part of the 2025 Pediatric Pharmacology Bundle. This course is a recorded presentation for NAPNAP's 20255 National Conference. The field of Allergy & Immunology continues to expand and incorporate new therapeutics to manage difficult diseases. In 2024, new drugs have been approved that can revolutionize treatment for disease management. Patients will look to their primary care clinicians to be knowledgeable and a resource for these therapeutics. This panel will include three NP experts from food allergy centers at the Children’s Hospital of Philadelphia and University of Texas Southwestern and will discuss biologics, immunotherapy options and non-IgE mediated disease updates for food allergy. NAPNAP’s Asthma and Allergy SIG is pleased to support this session. |
|
08/29/2025 to 08/31/2027 | $0.00 | $0.00 |
|
Influenza 2025-2026: Is Your Pediatric Practice Ready? 1.0 NAPNAP Contact Hour of which 0.75 contain pharmacology content. This continuing education activity is offered free for NAPNAP Members and non-members. As we enter influenza season, pediatric-focused APRNs can increase their knowledge and prepare to counsel families and restore confidence in influenza vaccines. This continuing education presentation will teach providers to balance communication of scientific data and vaccine efficacy with acknowledgment of parental concerns and fears, and help families feel empowered to make the best decisions when it comes to flu prevention. |
|
11/14/2025 to 11/30/2026 | $0.00 | $0.00 |
|
Leucovorin in Autism: An Evidence-Based and Clinically Informed Approach 1.25 NAPNAP Contact Hours of which 1.25 contains pharmacology content. This continuing education activity is offered free for NAPNAP Members and non-members. This presentation synthesizes the evidence on folinic acid in autism, with an emphasis on advances since 2018 within the context of foundational work. We will examine the pathophysiology of cerebral folate deficiency (CFD), clarify genetic contributors (e.g., FOLR1 and folate-pathway variants), and review clinical testing with folate receptor-α autoantibodies and related labs. Practical treatment guidance will cover formulation selection, dosing and titration, monitoring, adverse effects, and pharmacy/compounding and cost considerations. Taught by a clinician with extensive real-world experience, the presentation highlights where the evidence is strongest and how to implement it. Learners will finish with a concise, evidence-based framework for evaluating and managing CFD in autism within standard practice. |
|
11/12/2025 to 11/30/2027 | $0.00 | $0.00 |